Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
The RET gene encodes a receptor tyrosine kinase whose function is essential during the development of kidney and the intestinal nervous system. Germline mutations affecting one of five cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC). These mutations lead to the replacement of a cysteine by an alternate amino acid. Mutations of the RET gene are also the underlying genetic cause of Hirschsprung disease (HSCR), a congenital aganglionosis of the hindgut. In a fraction of kindreds, MEN 2A cosegregate with HSCR and affected individuals carry a single mutation at codons 609, 618 or 620. To examine the consequences of cysteine substitution on RET function, we have introduced a Cys to Arg mutation into the wild-type RET at either codons 609, 618, 620, 630 or 634. We now report that each mutation induces a constitutive catalytic activity due to the aberrant disulfide homodimerization of RET. However, mutations 630 and 634 activate RET more strongly than mutations 609, 618 or 620 as demonstrated by quantitative assays in rodent fibroblasts and pheochromocytoma PC12 cells. Biochemical analysis revealed that mutations 618 and 620, and to a lesser extent mutation 609, result in a marked reduction of the level of RET at the cell surface and as a consequence decrease the amount of RET covalent dimer. These findings provide a molecular basis explaining the range of phenotype engendered by alterations of RET cysteines and suggest a novel mechanism whereby mutations of cysteines 609, 618 and 620 exert both activating and inactivating effects.
Chappuis-Flament
S
S
Laboratoire de Génétique, CNRS UMR 5641, Domaine Rockefeller, Lyon, France.
Pasini
A
A
De Vita
G
G
Ségouffin-Cariou
C
C
Fusco
A
A
Attié
T
T
Lenoir
G M
GM
Santoro
M
M
Billaud
M
M
D016475:3T3 Cells; D019943:Amino Acid Substitution; D000818:Animals; D002471:Cell Transformation, Neoplastic; D003545:Cysteine / Q000235:genetics / Q000378:metabolism*; D019281:Dimerization; D004220:Disulfides; D029721:Drosophila Proteins; D006031:Glycosylation; D006627:Hirschsprung Disease / Q000201:enzymology / Q000235:genetics; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008954:Models, Biological; D018813:Multiple Endocrine Neoplasia Type 2a / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism; D016716:PC12 Cells; D019000:Phosphotyrosine / Q000378:metabolism; D011233:Precipitin Tests; D011518:Proto-Oncogene Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D051096:Proto-Oncogene Proteins c-ret; D051381:Rats; D020794:Receptor Protein-Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015533:Transcriptional Activation
D004220:Disulfides; D029721:Drosophila Proteins; D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; D019000:Phosphotyrosine; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases; C416649:Ret protein, Drosophila; C494999:Ret protein, mouse; C495001:Ret protein, rat; D003545:Cysteine